Program
ribitol
Also written as “BBP-418 (ribitol)” and “BBP-418”.
Its studies are mostly in Muscular Dystrophies, Limb-Girdle, led by BridgeBio.
Furthest: phase 3, since Feb 16, 20233 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BridgeBio | 33 open or running | phase 3since Feb 16, 2023 | Jan 25, 2021 | Sep 2027phase 3 · NCT05775848 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2021First study: phase 2 study in Muscular Dystrophy, Limb-Girdle, Type 2IFirst studyNCT04800874 · 14 enrolled · United States
- Feb 16, 2023Phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT05775848 · 112 enrolled · United States, Australia, Denmark and more
- Jun 25, 2026Phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT07678775 · 107 enrolled · United States, Australia, Denmark and more
Ahead
- Nov 1, 2026Primary completion: phase 2 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT04800874
- Sep 2027Primary completion: phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT05775848
- Oct 2030Primary completion: phase 3 study in Muscular Dystrophy, Limb-Girdle, Type 2INCT07678775
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07678775Muscular Dystrophy, Limb-Girdle, Type 2I · United States, Australia, Denmark and more | 3 | Active, not recruiting | Oct 2030 | 107 |
| NCT05775848Muscular Dystrophy, Limb-Girdle, Type 2I · United States, Australia, Denmark and more | 3 | Active, not recruiting | Sep 2027 | 112 |
| NCT04800874Muscular Dystrophy, Limb-Girdle, Type 2I · United States | 2 | Active, not recruiting | Nov 1, 2026 | 14 |
How it is read
Names in the registry
- “BBP-418 (ribitol)”, 2 entries
- “BBP-418”, 1 entry
Conditions, from the studies’ own filings
- Muscular Dystrophies, Limb-Girdle, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.